This poster is published under an
open license. Please read the
disclaimer for further details.
Keywords:
Lung, CT, Chemotherapy, Cancer
Authors:
W. Lu1, M. Cham2, J. Wang1, W. Tang1; 1Beijing/CN, 2New York, NY/US
DOI:
10.1594/ecr2016/C-0107
Methods and materials
We retrospectively studied patients with GGNs that met the following criteria: (1) GGNs found in patients with lung adenocarcinoma, which
persist for more than 3 months ; (2) Patients treated with platinum based (cisplatin or carboplatin) chemotherapy for at least 2 cycles; (3) Ground glass proportion ≥50% .
Patients whose follow-up periods were shorter than 6 months,
had confirmed pulmonary metastasis, progression of other malignancies, or lost to follow-up were excluded. All CT scans were performed at a single institution using 1.0 to 1.25 mm thick sections.
For each patient,
if more than 2 CTs satisfied the inclusion criteria,
then only the baseline and last CTs were used for analysis,
defined as CT1 and CT2.
A total of 91 persistent pulmonary GGNs in 51 patients fulfilled the inclusion criteria.
We defined growth as a nodule ≧2mm increase in diameter or showing up a solid portion.
GGN response to therapy was assessed and compared with the baseline CT.
Differences in CT findings were analyzed using a paired t-test and Pearson χ2 test.